تداخلات تيلميسارتان وأملوديبين

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (نشرة إبتيفيباتيد، موانع الاستعمال)

IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC and intravenous verapamil. (نشرة إسمولول، موانع الاستعمال)

هذه الأدوية تقلّل إطراح البوتاسيوم؛ وإضافة مكملات البوتاسيوم أو بدائل الملح قد تسبب فرط بوتاسيوم الدم، وهو يؤثر في نظم القلب. (NIH Office of Dietary Supplements, Potassium)

Do not co-administer aliskiren with telmisartan and amlodipine tablets in patients with diabetes [see Drug Interactions (7.2)]. (نشرة تيلميسارتان وأملوديبين، موانع الاستعمال)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Calcium Channel Blockers Felodipine Nisoldipine Contraindicated during and 2 weeks after TOLSURA treatment. (نشرة إيتراكونازول، التداخلات الدوائية)

Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function. (نشرة بيتاكسولول، التداخلات الدوائية)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (نشرة تادالافيل، التحذيرات والاحتياطات)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

The concomitant use of RYANODEX and calcium channel blockers is not recommended during the treatment of malignant hyperthermia. (نشرة دانترولين، التداخلات الدوائية)

Co-administration of telmisartan and ramipril is not recommended. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (نشرة سترات الحديديك، التداخلات الدوائية)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

…with colchicine; markedly increased transaminases with lomitapide; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia and cardiac arrhythmias (e.g., torsades de pointes) with disopyramide; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). (نشرة كلاريثرومايسين، التحذيرات والاحتياطات)

• Calcium Channel Blockers: Avoid concomitant use with Calcium Chloride Injection. (نشرة كلوريد الكالسيوم، التداخلات الدوائية)

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (نشرة كلوزابين، تحذير مؤطر)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

IV administration of non-dihydropyridine calcium-channel antagonists (e.g., verapamil) Hypersensitivity reactions, including anaphylaxis, to labetalol Bronchial asthma ( 4 ) (نشرة لابيتالول، موانع الاستعمال)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Avoid concomitant use with an ACE inhibitor (5.6) (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (نشرة ميتولازون، التحذيرات)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (نشرة مينوكسيديل، تحذير مؤطر)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (نشرة أتوموكسيتين، التداخلات الدوائية)

(See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (نشرة أتينولول، التحذيرات)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (نشرة أدرينالين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (نشرة أريبيبرازول، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة أسينابين، التحذيرات والاحتياطات)

CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (نشرة أفانافيل، التداخلات الدوائية)

Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (نشرة ألفوزوسين، التحذيرات والاحتياطات)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (نشرة أوكتريوتيد، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

…of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (نشرة أولانزابين، التحذيرات والاحتياطات)

…and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة أولانزابين وفلوكسيتين، التحذيرات والاحتياطات)

Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (نشرة إيبوبروستينول، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (نشرة إيبويتين ألفا، التحذيرات والاحتياطات)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. (نشرة إيزوسوربيد أحادي النترات، التداخلات الدوائية)

Calcium Antagonists FORANE may lead to marked hypotension in patients treated with calcium antagonists. (نشرة إيزوفلوران، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

If simvastatin is co-administered with amlodipine, do not exceed doses greater than 20 mg daily of simvastatin (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (نشرة إيلوبيريدون، التحذيرات والاحتياطات)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (نشرة بازوبانيب، التحذيرات والاحتياطات)

Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (نشرة باسيريوتيد، التحذيرات والاحتياطات)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة باليبيريدون، التحذيرات والاحتياطات)

Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (نشرة برازوسين، التحذيرات)

The concomitant use of beta-adrenergic blockers and non-dihydropyridine calcium channel blockers (e.g., verapamil and diltiazem), digoxin or clonidine increases the risk of significant bradycardia. (نشرة بروبرانولول، التحذيرات والاحتياطات)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (نشرة برومفينيرامين وسودوإيفيدرين وديكستروميثورفان، التداخلات الدوائية)

Use caution in patients taking antihypertensive medications. (نشرة بروموكريبتين، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (نشرة بريكسبيبرازول، التحذيرات والاحتياطات)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (نشرة بريمونيدين، التداخلات الدوائية)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (نشرة بنتوكسيفيلين، التداخلات الدوائية)

Amphetamines may decrease the hypotensive effect of antihypertensives. (نشرة بنزفيتامين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (نشرة بورتيزوميب، التحذيرات والاحتياطات)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (نشرة بيسوبرولول، التحذيرات)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended and adjust the dose when appropriate. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (نشرة ترازودون، التحذيرات والاحتياطات)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (نشرة تستوستيرون، التحذيرات والاحتياطات)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Monitor serum potassium during concomitant therapy with ( 7.2 ): Angiotensin receptor blockers Angiotensin converting enzyme inhibitors Potassium sparing diuretics 7.1 CYP3A Inhibitors and Inducers Strong CYP3A Inhibitors Tolvaptan's AUC was 5.4 times as large and C max was 3.5 times as large after co-administration of tolvaptan and 200 mg ketoconazole [see Warnings… (نشرة تولفابتان، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (نشرة تيرازوسين، التحذيرات والاحتياطات)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (نشرة تيمسيروليموس، التداخلات الدوائية)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (نشرة تيمولول، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants. (نشرة دروبيريدول، التداخلات الدوائية)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (نشرة دروسبيرينون وإيثينيل إستراديول، التحذيرات والاحتياطات)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد، التداخلات الدوائية)

Calcium Channel Antagonists Dutasteride Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (نشرة دوتاستيريد وتامسولوسين، التداخلات الدوائية)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (نشرة دورزولاميد وتيمولول، التداخلات الدوائية)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (نشرة دوفيتيليد، التداخلات الدوائية)

The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (نشرة دولوكسيتين، التحذيرات والاحتياطات)

The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (نشرة ديثيل بروبيون، التداخلات الدوائية)

Amlodipine (5 to 10 mg per day) has been studied in a placebo-controlled trial of 1153 patients with NYHA Class III or IV heart failure on stable doses of ACE inhibitor, digoxin, and diuretics. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

• Antihypertensive Drugs: Monitor blood pressure. (نشرة ديكسميثيل فينيدات، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (نشرة ريسبيريدون، التحذيرات والاحتياطات)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (نشرة ريوسيغوات، التحذيرات والاحتياطات)

Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة زيبراسيدون، التحذيرات والاحتياطات)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (نشرة سورافينيب، التحذيرات والاحتياطات)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Initiate and/or adjust antihypertensive therapy as appropriate. (نشرة سونيتينيب، التحذيرات والاحتياطات)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (نشرة سيفوفلوران، التداخلات الدوائية)

…concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (نشرة سيكلوبنزابرين، التداخلات الدوائية)

Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended and adjust the dose when appropriate. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. (نشرة سيلدينافيل، التحذيرات والاحتياطات)

However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (نشرة سيلودوسين، التحذيرات والاحتياطات)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

If simvastatin is co-administered with amlodipine, do not exceed doses greater than 20 mg daily of simvastatin (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Calcium Channel Blockers : Administration of calcium may reduce the response. (نشرة غلوكونات الكالسيوم، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (نشرة فاردينافيل، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (نشرة فينيلزين، التحذيرات)

Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (نشرة فينيليفرين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (نشرة كاربيدوبا، التداخلات الدوائية)

Antihypertensive drugs: May cause symptomatic postural hypotension. (نشرة كاربيدوبا وليفودوبا، التداخلات الدوائية)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (نشرة كاربيدوبا وليفودوبا وإنتاكابون، التداخلات الدوائية)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (نشرة كارفيديلول، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (نشرة كاريبرازين، التحذيرات والاحتياطات)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Drugs that affect sinus node function or AV node conduction (e.g., digitalis, calcium channel blockers, beta blockers) Clinical Implication Concomitant use of drugs that affect sinus node function or AV node conduction with clonidine potentiate bradycardia and risk of AV block [see Warnings and Precautions (5.1) ]. (نشرة كلونيدين، التداخلات الدوائية)

Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة كويتيابين، التحذيرات والاحتياطات)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (نشرة لاكوساميد، التحذيرات والاحتياطات)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (نشرة لوراسيدون، التحذيرات والاحتياطات)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (نشرة لوميتابيد، التداخلات الدوائية)

Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including telmisartan. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Examples: Drugs known to have potential to prolong QT interval: Class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers. (نشرة ميثادون، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Antihypertensive Drugs: Monitor blood pressure. (نشرة ميثيل فينيدات، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (نشرة ميرتازابين، التحذيرات والاحتياطات)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (نشرة ميفلوكين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (نشرة ميكاميلامين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Caution should also be used when niacin extended-release tablets are used in patients with unstable angina or in the acute phase of an MI, particularly when such patients are also receiving vasoactive drugs such as nitrates, calcium channel blockers, or adrenergic blocking agents. (نشرة نياسين، التحذيرات والاحتياطات)

Non-dihydropyridine Calcium Channel Blockers Because of significant negative inotropic and chronotropic effects in patients treated with β-blockers and calcium channel blockers of the verapamil and diltiazem type, monitor the ECG and blood pressure in patients treated concomitantly with these agents. (نشرة نيبيفولول، التحذيرات والاحتياطات)

Antihypertensives: Possible additive hypotensive effects. (نشرة نيتروغليسرين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

CYP3A4 Inhibitors Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (نشرة نيموديبين، التداخلات الدوائية)

Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. (نشرة تيلميسارتان وأملوديبين، التحذيرات والاحتياطات)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

…propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem,… (نشرة وارفارين، التداخلات الدوائية)

Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (نشرة أدينوزين، التداخلات الدوائية)

In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (نشرة إسراديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (نشرة إيفيدرين، التداخلات الدوائية)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (نشرة إيكاتيبانت، التداخلات الدوائية)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (نشرة بروتريبتيلين، التحذيرات)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (نشرة بروكلوربيرازين، الاحتياطات)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (نشرة بوتورفانول، التحذيرات)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (نشرة تريفلوبيرازين، الاحتياطات)

There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (نشرة تيربينافين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

…malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants. [see Contraindications (4), Clinical Pharmacology (12.5)] Signs consistent with malignant hyperthermia may include hyperthermia, hypoxia,… (نشرة ديسفلوران، التحذيرات والاحتياطات)

If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (نشرة ديسوجيستريل وإيثينيل إستراديول، التحذيرات)

This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (نشرة ديسيبرامين، التحذيرات)

Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (نشرة ديكستروأمفيتامين، التداخلات الدوائية)

No other formal drug-drug interaction studies between zafirlukast and marketed drugs known to be metabolized by the P450 3A4 (CYP3A4) isoenzyme (e.g., dihydropyridine calcium-channel blockers, cyclosporin, cisapride) have been conducted. (نشرة زافيرلوكاست، الاحتياطات)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

QUELICIN can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants. [see Contraindications (4) , Clinical Pharmacology (12.5) ] . (نشرة سكسينيل كولين، التحذيرات والاحتياطات)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

…studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives… (نشرة فيناستيريد، التداخلات الدوائية)

CYP3A4 Inducers No information is available on the quantitative effects of CYP3A4 inducers ( e.g., carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone, rifampicin, St. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (نشرة كلوربرومازين، التحذيرات)

Interactions with other dihydropyridine calcium channel blockers have not been reported, but these agents (including felodipine, nicardipine, and nimodipine ) are all dependent upon P450 IIIA4 for metabolism, so similar interactions with quinidine should be anticipated. (نشرة كينيدين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (نشرة ميثيل دوبا، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (نشرة ميكسيليتين، التداخلات الدوائية)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (نشرة نيتروبروسيد، التحذيرات)

The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (نشرة نيسولديبين، التداخلات الدوائية)

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (نشرة هيدرالازين، التداخلات الدوائية)

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Amlodipine has no clinically relevant effects on the pharmacokinetics or pharmacodynamics of the following: atorvastatin, digoxin, warfarin. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

The following have no clinically relevant effects on the pharmacokinetics of amlodipine: cimetidine, grapefruit juice, magnesium and aluminum hydroxide antacid, sildenafil. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

The following have no clinically relevant effects on the pharmacokinetics of amlodipine: cimetidine, grapefruit juice, magnesium and aluminum hydroxide antacid, sildenafil. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Calcium channel blocking agents: Coadministration of calcium channel blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials. (نشرة إيبوتيليد، التداخلات الدوائية)

The following have no clinically relevant effects on the pharmacokinetics of amlodipine: cimetidine, grapefruit juice, magnesium and aluminum hydroxide antacid, sildenafil. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

The following have no clinically relevant effects on the pharmacokinetics of amlodipine: cimetidine, grapefruit juice, magnesium and aluminum hydroxide antacid, sildenafil. (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)